Performance Measures

AGA's Role

AGA has been a leader in performance measurement since 2006 and has developed measures for several digestive health conditions and clinical topics including: colorectal cancer screening and surveillance (CRC), hepatitis C (HCV) and inflammatory bowel disease (IBD).

The AGA Institute Quality Measures Committee provides clinical and methodological expertise and oversight for the development, specification, maintenance and testing of AGA's performance measures.

Public Comments

Responses to public comments received for three new AGA performance measures now are available for review:

Endoscopy/Barrett’s esophagus surveillance: Systematic biopsies during surveillance esophagoscopy or esophagogastroduodenoscopy (EGD) in patients with Barrett’s esophagus without dysplasia – Adequacy of surveillance

Endoscopy/Barrett’s esophagus surveillance: Esophagoscopy or esophagogastroduodenoscopy (EGD) interval for patients with non-dysplastic Barrett’s esophagus – Avoidance of Inappropriate Use

Hepatitis C Virus/Liver Disease:  Patients with Cirrhosis, Surveillance for Developing Hepatocellular Carcinoma (HCC)

 

 

Measures

Inflammatory Bowel Disease (IBD)
Jan. 1, 2016
AGA maintains IBD measures.

Hepatitis C (HCV)
Jan. 1, 2016
AGA maintains HCV and other liver disease measures in collaboration with AASLD.

Colorectal Cancer (CRC) Screening and Surveillance
Jan. 1, 2016
AGA maintains endoscopy measures in collaboration with ACG and ASGE.